Clinical Trials Logo

Complement Mediated Diseases clinical trials

View clinical trials related to Complement Mediated Diseases.

Filter by:
  • None
  • Page 1

NCT ID: NCT03316521 Completed - Clinical trials for Complement Mediated Diseases

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Start date: April 24, 2017
Phase: Phase 1
Study type: Interventional

Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101. A prospective, single-center, open-label, First-In-Human (FIH) clinical study in healthy male volunteers.